Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522180 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04522180 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 34 participants.
The verdict
NCT04522180, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
Interventions
- DRUG GHR-LRX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2023-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04522180
The ClinicalTrials.gov registry entry for NCT04522180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GHR-LRX is the first listed.
NCT04522180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04522180 about?
NCT04522180 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly". The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
What is the current status of trial NCT04522180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2021-01-04. Estimated completion is 2023-05-04.
What interventions are being tested in trial NCT04522180?
The interventions under investigation include: GHR-LRX (DRUG).
Who is sponsoring clinical trial NCT04522180?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.